+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Glioblastoma (GBM)

  • Report

  • 54 Pages
  • May 2021
  • Region: Global
  • Citeline
  • ID: 4846134
This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2019, there were 77,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 91,800 incident cases by 2028.
  • It is estimated that the majority of diagnosed cases were in males in 2019. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intratumoral, and oral routes for glioblastoma.
  • The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with only one drug in the NDA/BLA phase.
  • Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.
  • High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I trial results, topline Phase I/II trial results, topline Phase II trial results, topline Phase III trial results, Phase III updated trial results, and an expected PDUFA date.
  • The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
  • The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
  • Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 80 trials.
  • Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, closely followed by Roche.

Table of Contents

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Tumor-treating fields (TTFs)
  • Targeted therapy

  • DNX-2401 for Glioblastoma (November 20, 2020)
  • Omburtamab for Glioblastoma (October 16, 2020)
  • AG-881 for Glioblastoma (May 29, 2020)
  • FT-2102 for Glioblastoma (May 28, 2020)

  • Innovent’s Adalimumab And Bevacizumab Get New Indications In China
  • New Approvals In Spotlight As China Gears For National Congress

  • Lineage, Immunomic Partner On Brain Cancer Immunotherapy
  • UroGen, Johns Hopkins Investigate Brain Cancer Immunotherapy
  • Simcere Picks Up Kazia’s Paxalisib In China-Plus Area
  • Chimerix Pays $78m To Acquire Oncoceutics
  • Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
  • Connectyx Explores Use Of NCI Antibody For Brain Cancer
  • Telix Chooses China Grand In Greater China Alliance
  • City of Hope Licenses CTLX-CAR-T Candidate To Chimeric
  • Cytovia Obtains Rights To CytoImmune’s CAR Candidate

  • Sponsors by status
  • Sponsors by phase
  • Recent Events

Figure 1: Trends in incident cases of glioblastoma, 2019–28
Figure 2: Overview of pipeline drugs for glioblastoma in the US
Figure 3: Pipeline drugs for glioblastoma, by company
Figure 4: Pipeline drugs for glioblastoma, by drug type
Figure 5: Pipeline drugs for glioblastoma, by classification
Figure 6: DNX-2401 for Glioblastoma (November 20, 2020): Phase II - CAPTIVE/KEYNOTE-192 - w/Keytruda
Figure 7: Omburtamab for Glioblastoma (October 16, 2020): Phase II/III - 101 (Neuroblastoma Central Nervous System/Leptomeningeal Metastases)
Figure 8: FT-2102 for Glioblastoma (May 28, 2020): Phase I/II - 2101-ONC-102
Figure 9: Key upcoming events in glioblastoma
Figure 10: Probability of success in the solid tumors pipeline
Figure 11: Clinical trials in glioblastoma
Figure 12: Top 10 drugs for clinical trials in glioblastoma
Figure 13: Top 10 companies for clinical trials in glioblastoma
Figure 14: Trial locations in glioblastoma
Figure 15: Glioblastoma trials status
Figure 16: Glioblastoma trials sponsors, by phase
Table 1: Global incident cases of glioblastoma, 2019–28
Table 2: Incident cases of glioblastoma, by gender, 2019
Table 3: Marketed drugs for glioblastoma
Table 4: Pipeline drugs for glioblastoma in the US
Table 5: DNX-2401 for Glioblastoma (November 20, 2020)
Table 6: Omburtamab for Glioblastoma (October 16, 2020)
Table 7: AG-881 for Glioblastoma (May 29, 2020)
Table 8: FT-2102 for Glioblastoma (May 28, 2020)
Table 9: Historical global sales, by drug ($m), 2016–20
Table 10: Forecasted global sales, by drug ($m), 2021–25